Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 8,175Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 15Sprycel

PharmaCompass

01

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 2,140

2019 Revenue in Millions : 2,110

Growth (%) : 1

blank

02

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 298

2019 Revenue in Millions : 294

Growth (%) : 1

blank

03

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 2,117

2020 Revenue in Millions : 2,140

Growth (%) : -1

blank

04

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 2,165

2021 Revenue in Millions : 2,117

Growth (%) : 2

blank

05

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,930

2022 Revenue in Millions : 2,165

Growth (%) : -11

blank

06

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2014 Revenue in Millions : 16.60%

2013 Revenue in Millions :

Growth (%) :

blank

07

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 1,493

2014 Revenue in Millions : 1,620

Growth (%) : 9%

blank

08

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 2,005

2016 Revenue in Millions : 1,824

Growth (%) : 10

blank

09

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,824

2015 Revenue in Millions : 1,620

Growth (%) : 13

blank

10

Brand Name : Sprycel

Dasatinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Sprycel

arrow
Medlab Asia & Asia Health
Not Confirmed

Dasatinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 2,000

2017 Revenue in Millions : 2,005

Growth (%) : -0.20%

blank